CTI BioPharma Corp. (CTIC) is a Biotechnology company in the Healthcare sector, currently trading at $9.10. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CTIC = $10 (+14.3% upside).
Financials: revenue is $54M, -100%/yr average growth. Net income is $91M (loss), growing at -34.9%/yr. Net profit margin is -168.8% (negative). Gross margin is 93.5% (-6.5 pp trend).
Balance sheet: total debt is $50M with negative equity of -$18M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.23 (adequate). Debt-to-assets is 39.7%. Total assets: $126M.
Analyst outlook: 13 / 19 analysts rate CTIC as buy (68%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 25/100 (Fail), Moat 47/100 (Partial), Future 61/100 (Pass), Income 10/100 (Fail).
